Cobio Diagnostics

Rapid detection of phage‑amplified protein signatures compatible with established clinical microbiology workflows. No reliance on colony monoculture: Diagnostic phage amplification is compatible with polymicrobial specimens

There is an urgent need for more rapid tests to identify the causative organisms responsible for bacterial infections as well as drug effectiveness and dose.

The company received a $984,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF), scheduled to begin in September 2024.

The company received a $249,500 Early-Stage Capital and Retention Grant from the Colorado Office of Economic Development and International Trade (OEDIT), which commenced in April 2024.

Cobio is developing a next‑generation, phage‑amplified diagnostic platform for rapid bacterial identification, antimicrobial susceptibility testing, and minimum inhibitory concentration determination directly from clinical specimens.

Cobio Diagnostics develops rapid diagnostic tools for urinary tract infections. The company receives a $2.2 million NIH SBIR Fast-Track grant to accelerate its technology. The funding supports research and development of faster, more efficient infection detection methods.

Aug 2026Fitzsimons Innovation CommunityNews article

Cobio secures a **$2.2 million NIH SBIR Fast-Track grant** from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance a **rapid bacterial infection diagnostic**. The funding supports development of a tool enabling clinicians to identify and treat infections within a single hospital shift. The award begins this month and accelerates Cobio’s mission in precision diagnostics for infectious diseases.

Aug 2026Cobio Diagnostics, IncNews article

Cobio secures a U.S. patent for its antimicrobial identification technology, developed by Chris Cox and Andy Logan. The method enables precise detection of effective antimicrobial agents and their concentrations. This breakthrough supports efforts to combat infectious diseases and antimicrobial resistance.

May 2026Cobio Diagnostics, IncNews article

A startup receives a **$984,000 NSF SBIR Phase II grant** to advance its rapid bacterial infection diagnostic, targeting treatment within a single clinical shift. The funding, effective September 2024, supports development of a tool designed to improve clinician decision-making for infection cases. The award aligns with the company’s goal of reducing delays in bacterial infection treatment.

Aug 2024Cobio Diagnostics, IncNews article